Table 5.
The prognosis value of IGF2BPs in cancers.
| System | Cancer type | IGF2BPs | Role of IGF2BPs in prognosis | References |
|---|---|---|---|---|
| Head and neck | HNSCC | 1 | Antibody responses to IGF2BP1 have a poor prognosis | 271 |
| HNSCC | 2 | Associated with T stage and poor prognosis | 272 | |
| OSCC, TSCC, NPC | 3 | Predicts poor outcome | 40,273,274 | |
| Endocrine system | PTC | 2 | A four-m6A-regulator signature including IGF2BP2 predicts poor prognosis | 210 |
| TC | 2 | A protective factor in the six-gene risk signature | 216 | |
| Poorly differentiate thyroid cancer | 3 | Associated with an increased risk of death, metastases, and DFS | 275 | |
| Respiratory system | NSCLC | 1 | Associated with male, cancer size, non-adenocarcinoma, smoking history, and poor prognosis | 200 |
| Lung cancer | 1 | A three-m6A-regulator signature including IGF2BP1 is related to OS, cancer status, and some clinical traits (gender, smoking history, etc.) | 208 | |
| LUAD | 3 | High expression of IGF2BPs predicts poorer OS and DFS | 276,277 | |
| Breast | Breast cancer | 1 | An independent prognostic factor; associated with shorter OS | 278 |
| Breast cancer | 2/3 | IGF2BP2/3, YTHDC2, and RBM15 could be used for the prognostic stratification of luminal A/B subtypes | 279 | |
| TNBC | 3 | Associated with a more aggressive phenotype and decreased OS | 280 | |
| Malignant phyllodes tumor of the breast | 3 | Associated with shorter periods of metastasis-free and DFS | 281 | |
| Metaplastic breast carcinoma | 3 | Related to poor OS | 282 | |
| Digestive system | ESCC | 3 | Associated with adverse clinical outcomes in patients treated with surgery alone | 283 |
| Esophageal adenocarcinoma | 3 | Associated with depth of cancer infiltration, lymph node metastases, and worse outcome | 202 | |
| Pancreatic cancer | 1/2 | Associated with poor prognosis | 44,45 | |
| Pancreatic ductal adenocarcinoma | 3 | Related to poor OS | 284 | |
| Intraductal papillary mucinous neoplasm | 3 | High expression of IGF2BP3 is related to shorter disease-specific survival | 192 | |
| Gastric adenocarcinoma | 3 | Predicts postoperative peritoneal dissemination and poor prognosis | 285 | |
| GC | 1 | High IGF2BP1 mRNA expression has poorer OS | 201 | |
| GC | 2 | Gene polymorphisms might be an independent predictor of chemotherapeutic response in patients with metastatic GC | 286 | |
| GC | 3 | Associated with poor disease-specific survival | 48 | |
| CRC | 1/2 | An independent poor prognostic marker | 17,152 | |
| HCC | 2 | Might be an independent risk factor | 32 | |
| HCC | 3 | Predicts early recurrence and poor prognosis | 203 | |
| Intrahepatic cholangiocarcinoma | 3 | Provides an independent prognostic value | 35 | |
| Gallbladder adenocarcinoma | 3 | Associated with high histological grade, advanced stage, lymphatic invasion, and worse OS | 287 | |
| Adenocarcinoma of the ampulla of Vater | 3 | Independently predicts shorter recurrence-free and OS | 288 | |
| Reproductive system | Endometrial cancer | 1 | High expression is associated with poor prognosis | 159 |
| Ovarian cancer | 1 | A three-m6A-regulator including IGF2BP1 signature predicts poor prognosis | 207 | |
| Ovarian clear cell carcinoma | 3 | Related to poor OS | 289 | |
| Uterine cancer | 1 | A pan-prognostic regulator | 290 | |
| Uterine corpus endometrial carcinoma | 3 | A three-m6A-regulator signature including IGF2BP3 predicts a poor prognosis | 209 | |
| Testicular germ cell tumor | 1 | A six-m6A-regulator signature including IGF2BP1 predicts a poor prognosis | 291 | |
| Prostate cancer | 3 | Has no independent prognostic value | 213,214 | |
| Prostate cancer | 3 | High IGF2BP3 serum levels are related to patients' poor prognosis | 292 | |
| Urinary system | ccRCC | 2 | The six-gene signature including IGF2BP2 is an independent risk factor for OS | 293 |
| ccRCC | 3 | An independent risk factor for localized CCRCC patients | 205 | |
| ccRCC | 3 | High co-expression of DMDRMR and IGF2BP3 is associated with poor outcomes | 95 | |
| Primary papillary renal cell carcinoma and ccRCC | 3 | An independent prognostic biomarker for identifying patients with distant metastasis risk | 294 | |
| Renal cell carcinoma | 3 | An independent prognostic biomarker related to metastasis and reduced 5-year OS | 204 | |
| Bladder cancer | 1/3 | Significantly associated with poor prognosis | 110,295 | |
| Aggressive urothelial carcinoma of the bladder | 3 | An independent prognostic biomarker; can identify patients who may benefit from early aggressive therapy | 296 | |
| Upper tract urothelial carcinoma | 3 | Independently associated with disease recurrence, cancer-specific mortality, and all-cause mortality | 297 | |
| Urachal carcinoma of the bladder | 3 | Has no prognostic significance | 212 | |
| Nervous system | Neuroblastoma | 1/3 | Predicts poorer prognosis | 206,298 |
| Neuroblastoma | 2 | A protective factor in the five-gene signature | 215 | |
| Glioma | 2 | Associated with poor OS and DFS | 62 | |
| Glioblastoma | 3 | A nine-gene signature is an independent risk factor for OS | 211 | |
| Hematopoietic system | AML, diffuse large b-cell lymphoma | 1/2/3 | Predicts poor OS | 299 |
| B-ALL | 3 | Portends a favorable survival high-risk B-ALL | 300 | |
| Skin | Melanoma | 3 | Predicts poor prognosis | 301 |
| Neuroendocrine tumor | Lung neuroendocrine tumor | 3 | Related to poor OS and DFS | 302 |
| Sarcoma | Osteosarcoma | 1 | Associated with high tumor grade, metastasis, recurrence, and poor response to chemotherapy | 303 |
| Osteosarcoma | 2 | An independent risk factor for OS and DFS | 304 | |
| Soft-tissue sarcoma | 1 | Patients with loss of IGF2BP1 have poorer DFS | 217 | |
| Uterine leiomyosarcoma | 3 | An independent risk factor | 305 | |
| Ewing sarcoma | 3 | Associated with poor OS | 91,249 |
B-ALL: B cell-acute lymphoblastic leukemia; ccRCC: clear cell renal carcinoma; CRC: colorectal cancer; ESCC: esophageal squamous cell carcinoma; GC: gastric cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; LUAD: lung adenocarcinoma; NPC: nasopharyngeal carcinoma; NSCLC: non-small cell lung cancer; OSCC, oral squamous cell carcinoma; PTC: papillary thyroid cancer; TC: thyroid cancer; TNBC: triple-negative breast cancer.